Recently, the efficacy of immune checkpoint inhibitors has been reported, and pembrolizumab has been approved as a second-line treatment in advanced PD-L1–positive cervical cancer.13-15 However, the responses achieved by programmed death protein 1(PD-1) inhibitors were modest. Here, CD274 is linked to cervical cancer.